Search research articles
Contact Us
Filters
Showing results (131-140 of 200) with videos related to
Page
of 20
Sort By:
Leukemia
|
May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Hematology (Amsterdam, Netherlands)
|
February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Hans Salwender, Niels Weinhold, Axel Benner, et al.
Haematologica
|
April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Maximilian Merz, Hans Salwender, Mathias Haenel, et al.
Journal of Cancer Research and Clinical Oncology
|
April 11, 2014
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia
Markus Pfirrmann, Susanne Saussele, Andreas Hochhaus, et al.
European Journal of Haematology
|
April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE
Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Blood Advances
|
July 15, 2024
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms
Yves Chalandon, Diderik-Jan Eikema, Ivan Moiseev, et al.
International Journal of Molecular Sciences
|
June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
Anja Seckinger, Hans Salwender, Hans Martin, et al.
Bone Marrow Transplantation
|
June 6, 2026
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT
Guillaume Dachy, Jarl E Mooyaart, Ludovic Gabellier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Bone Marrow Transplantation
|
August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT
Noureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Page
of 20
Search research articles
Search
Showing results (131-140 of 200) with videos related to
Sort By:
Page
of 20
Leukemia
|
May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Hematology (Amsterdam, Netherlands)
|
February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Hans Salwender, Niels Weinhold, Axel Benner, et al.
Haematologica
|
April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Maximilian Merz, Hans Salwender, Mathias Haenel, et al.
Journal of Cancer Research and Clinical Oncology
|
April 11, 2014
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia
Markus Pfirrmann, Susanne Saussele, Andreas Hochhaus, et al.
European Journal of Haematology
|
April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE
Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Blood Advances
|
July 15, 2024
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms
Yves Chalandon, Diderik-Jan Eikema, Ivan Moiseev, et al.
International Journal of Molecular Sciences
|
June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
Anja Seckinger, Hans Salwender, Hans Martin, et al.
Bone Marrow Transplantation
|
June 6, 2026
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT
Guillaume Dachy, Jarl E Mooyaart, Ludovic Gabellier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Bone Marrow Transplantation
|
August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT
Noureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Page
of 20